Compare IHRT & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHRT | BBNX |
|---|---|---|
| Founded | 1974 | 2015 |
| Country | United States | United States |
| Employees | 9550 | 423 |
| Industry | Broadcasting | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 589.5M | 493.1M |
| IPO Year | N/A | N/A |
| Metric | IHRT | BBNX |
|---|---|---|
| Price | $3.55 | $16.06 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $4.25 | ★ $23.80 |
| AVG Volume (30 Days) | 725.4K | ★ 994.2K |
| Earning Date | 05-11-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.96 | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.54 | $8.80 |
| 52 Week High | $6.56 | $32.71 |
| Indicator | IHRT | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 50.51 |
| Support Level | $3.61 | $9.34 |
| Resistance Level | $3.73 | $32.52 |
| Average True Range (ATR) | 0.21 | 1.17 |
| MACD | -0.03 | -0.25 |
| Stochastic Oscillator | 25.07 | 18.16 |
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.